Cinzia Lavarino

TL;DR: A significant correlation has been found between p53 accumulation, type of mutation, and pathological response to cisplatin-based therapy in ovarian cancer patients, consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.

TL;DR: A small panel of cytogenetic biomarkers is identified that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.

TL;DR: Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma, and patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy.

TL;DR: The absence of mdm2 and p53 reactivity in lipomas seems to represent a useful marker for differential diagnosis from lipoma‐like WD liposarcomas and non‐retroperitoneal WD–DD group, where the TP53 mutations appear to correlate with the dedifferentiation process.

TL;DR: The results indicate that, in MPNSTs, p16INK4A inactivation almost equally affects both groups, and TP53 mutations and loss of heterozygosity involving the TP53 locus, and p53 wild type overeexpression, related or not to mdm2 overexpression, seem to mainly be restricted to sporadic MPN STs.